• Profile
Close

Chemoradiotherapy vs chemotherapy as adjuvant treatment for localized gastric cancer: A propensity score-matched analysis

BMC Cancer Apr 11, 2018

Girardi DM, et al. - Overall survival (OS) benefits with chemoradiation (CRT) vs chemotherapy (CT) were determined when administered as adjuvant treatment for patients with localized gastric cancer (LGC) treated at Instituto do Cancer do Estado de Sao Paulo (ICESP) from 2012 to 2015. CRT was based on the INT-0116 regimen and CT consisted of a platinum and fluoropyrimidine doublet. A median follow-up of 23.5 months (CRT) and 20.6 months (CT) revealed no difference in OS between groups. In CRT and CT groups, the following were reported as the most prevalent grade 3/4 toxicities: nausea/vomiting (9.25 vs 4.9%), fatigue (9.3% vs 2.4%), mucositis (4.4% vs 1.2%), neutropenia (37.8% vs 20.9%), febrile neutropenia (3.9% vs 0%), anemia (4.3% vs 6.1%), thrombocytopenia (2.6% vs 4.9%), neuropathy (0 vs 2.4%) and hand-foot syndrome (0.4% vs 2.4%). Overall, similar efficacy, as well as tolerability of CT and CRT, was shown when given as adjuvant treatment for LGC.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay